| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 02/25/2014 | CA2621127C Treatment with an oncolytic virus and an immunostimulant for in vivo enhancement of immune system recognition of neoplasms |
| 02/25/2014 | CA2592627C Vaccine composition comprising a fibronectin binding protein or a fibronectin binding peptide |
| 02/25/2014 | CA2544949C Antagonist anti-cd40 monoclonal antibodies and methods for their use |
| 02/25/2014 | CA2538252C 4'-thionucleosides and oligomeric compounds |
| 02/25/2014 | CA2505325C Stabilized single domain antibodies |
| 02/20/2014 | WO2014028925A1 Gene expression profile associated with prostate cancer |
| 02/20/2014 | WO2014028865A1 Compositions and methods for detecting complement activation |
| 02/20/2014 | WO2014028852A1 Use of p47 from plasmodium falciparum (pfs47) or plasmodium vivax (pvs47) as a vaccine or drug screening targets for the inhibition of human malaria transmission |
| 02/20/2014 | WO2014028748A1 Interleukin 2 antibodies and antibody complexes |
| 02/20/2014 | WO2014028668A2 Stem cell enhancing therapeutics |
| 02/20/2014 | WO2014028644A1 Methods and compositions for preventing a condition |
| 02/20/2014 | WO2014028560A2 T-cell redirecting bispecific antibodies for treatment of disease |
| 02/20/2014 | WO2014028511A1 Attenuated live vaccine for crimean-congo hemorrhagic fever virus and erve virus |
| 02/20/2014 | WO2014028502A1 Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases |
| 02/20/2014 | WO2014028446A1 Anti-jagged anitbodies and methods of use |
| 02/20/2014 | WO2014028354A1 Anti-pcsk9 antibodies with ph-dependent binding characteristics |
| 02/20/2014 | WO2014028222A1 Biomarkers for identifying esophageal cancer patients for treatment with an anti-egfr drug |
| 02/20/2014 | WO2014028221A1 Histological markers for identifying non-small cell lung carcinoma patients for treatment with an anti-egfr drug |
| 02/20/2014 | WO2014027959A1 Angiopoietin-like 4 antibody and a method of its use in cancer treatment |
| 02/20/2014 | WO2014027899A1 NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATION |
| 02/20/2014 | WO2014027656A1 METHOD FOR INCREASING DEPOSITION OF COMPLEMENT C3b ON BACTERIAL CELL SURFACES AND PHAGOCYTIC ACTIVITY OF PHAGOCYTES, AND METHOD AND AGENT FOR TREATING BACTERIAL INFECTION |
| 02/20/2014 | WO2014027626A1 MONOCLONAL IgE ANTIBODY BONDING TO SWEAT ALLERGY ANTIGEN PROTEIN |
| 02/20/2014 | WO2014027084A1 An immunogenic composition of killed leptospira bacteria |
| 02/20/2014 | WO2014027083A1 An immunogenic composition of killed leptospira bacteria |
| 02/20/2014 | WO2014027082A1 Enhanced rapid immunogen selection method for hiv gp120 variants |
| 02/20/2014 | WO2013186630A3 Humanized antibodies to ca215 |
| 02/20/2014 | WO2013183032A3 Humanized anti-trka antibodies with amino acid substitutions |
| 02/20/2014 | WO2013177595A3 Recombinant influenza viruses and constructs and uses thereof |
| 02/20/2014 | WO2013177062A3 Methods for improving safety of blood-brain barrier transport |
| 02/20/2014 | WO2013128274A3 Recombinant microorganisms and uses thereof |
| 02/20/2014 | WO2013117742A3 Pharmaceutical composition for the treatment of multiple sclerosis |
| 02/20/2014 | WO2012177658A8 Methods of treating and preventing staphylococcus aureus infections and associated conditions |
| 02/20/2014 | WO2012162068A3 Deimmunized serum-binding domains and their use for extending serum half-life |
| 02/20/2014 | WO2012158529A3 Compositions and methods for immunization against drug resistant acinetobacter baumannii |
| 02/20/2014 | WO2012149365A3 Antibodies selective for pathological tau dimers and oligomers and their uses in treatment, diagnosis, monitoring of tauopathies |
| 02/20/2014 | WO2012149045A3 Liposomal formulations |
| 02/20/2014 | WO2012142320A8 Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| 02/20/2014 | US20140051838 Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer |
| 02/20/2014 | US20140051145 Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers |
| 02/20/2014 | US20140051096 Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers |
| 02/20/2014 | US20140050780 Liposomal formulation of nonglycosidic ceramides and uses thereof |
| 02/20/2014 | US20140050776 Novel method for preventing or treating m tuberculosis infection |
| 02/20/2014 | US20140050764 Inactivated Bacterial Cell Formulation |
| 02/20/2014 | US20140050763 Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases |
| 02/20/2014 | US20140050761 Crimean-Congo Hemorrhagic Fever Virus Vaccine |
| 02/20/2014 | US20140050759 Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza a viruses |
| 02/20/2014 | US20140050755 Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use |
| 02/20/2014 | US20140050754 Immunogenic chikungunya virus peptides |
| 02/20/2014 | US20140050752 Vaccinia virus polypeptides |
| 02/20/2014 | US20140050750 Vaccine peptide combinations against cat allergy |
| 02/20/2014 | US20140050742 Methods and compositions for modulating lymphangiogenesis, e.g., to treat transplant rejection, in a subject |
| 02/20/2014 | US20140050740 Compositions and methods for the treatment of tissue fibrosis |
| 02/20/2014 | US20140050739 Local complement inhibition for treatment of complement-mediated disorders |
| 02/20/2014 | US20140050735 Treatment of fistulizing chrohn's disease |
| 02/20/2014 | US20140050734 Antibodies against the s100p protein for the treatment and diagnosis of cancer |
| 02/20/2014 | US20140050732 Combination for use in the treatment and/or prevention of mastitis |
| 02/20/2014 | US20140050731 Vaccine |
| 02/20/2014 | US20140050730 Methods for diagnosing and treating neuroendocrine cancer |
| 02/20/2014 | US20140050729 Methods for treatment of polyposis |
| 02/20/2014 | US20140050728 Methods and compositions for inhibiting cyclophilin d for the treatment and prevention of obesity and kidney indications |
| 02/20/2014 | US20140050721 Antineoplastic Combinations with mTOR Inhibitor, Trastuzumab and/or HKI-272 |
| 02/20/2014 | US20140050718 Methods and Compositions for Enhancing Intranasal Delivery of Therapeutic Agents |
| 02/20/2014 | US20140050661 Novel anti-cxcr4 antibodies and their use for the treatment of cancer |
| 02/20/2014 | US20140050660 T-Cell Redirecting Bispecific Antibodies for Treatment of Disease |
| 02/20/2014 | CA2874864A1 T-cell redirecting bispecific antibodies for treatment of disease |
| 02/19/2014 | EP2698382A1 Human immune therapies using a CD27 agonist alone or in combination with other immune modulators |
| 02/19/2014 | EP2698380A1 Neutralizing molecules to viral antigens |
| 02/19/2014 | EP2698377A1 Enhanced rapid immunogen selection method for HIV gp120 variants |
| 02/19/2014 | EP2698166A2 Complement inhibition for improved nerve regeneration |
| 02/19/2014 | EP2698165A1 Cytotoxic immunoglobulin |
| 02/19/2014 | EP2698164A1 Dna vaccine |
| 02/19/2014 | EP2698158A1 Immunomodulation by IAP Inhibitors |
| 02/19/2014 | EP2697651A1 Biomarkers for pain intensity |
| 02/19/2014 | EP2697385A1 Fermentation process |
| 02/19/2014 | EP2697371A1 Derivative of the lactobacilus johnsonii strain cncm i-1225, deficient in d-lactic acid production and with an improved shelf life |
| 02/19/2014 | EP2697367A1 Method for proliferation of antigen-specific t cells |
| 02/19/2014 | EP2697259A1 Compositions for preventing and/or treating an infection by an hiv-1 virus |
| 02/19/2014 | EP2697256A1 Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer |
| 02/19/2014 | EP2696898A2 Compositions comprising saccharide binding moieties and methods for targeted therapy |
| 02/19/2014 | EP2696895A1 IMMUNOAFFINITY SEPARATION MATERIALS COMPRISING ANTI-IgE ANTIBODY DERIVATIVES |
| 02/19/2014 | EP2696894A2 Method for priming of t cells |
| 02/19/2014 | EP2696893A1 Vaccine against pasteurellaceae |
| 02/19/2014 | EP2696892A2 Combination vaccine against staphyloccal infections |
| 02/19/2014 | EP2696891A1 New vaccines for prevention and treatment of tuberculosis |
| 02/19/2014 | EP2696888A2 Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| 02/19/2014 | CN103597072A Proliferating agent for monocyte, culture medium for proliferating monocyte, method for producing monocyte, method for producing dendritic cell, and method for producing dendritic cell vaccine |
| 02/19/2014 | CN103596983A Anti-FGFR4 antibodies and methods of use |
| 02/19/2014 | CN103596982A Therapeutic antibodies |
| 02/19/2014 | CN103596980A FGFR1 agonists and methods of use |
| 02/19/2014 | CN103596978A Anti-IL-12/IL-23 antibodies and uses thereof |
| 02/19/2014 | CN103596975A Recombinant human bivalent diabody against rabies virus and uses thereof |
| 02/19/2014 | CN103596974A Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer |
| 02/19/2014 | CN103596593A Anti-CD40 antibodies and uses thereof |
| 02/19/2014 | CN103596592A Methods for preventing toxic drug-drug interactions in combination therapies comprising anti-ErbB3 agents |
| 02/19/2014 | CN103596591A Treatment of osteoarthritis and pain |
| 02/19/2014 | CN103596590A Cd37-binding molecules and immune conjugates thereof |
| 02/19/2014 | CN103596589A Treatment for peanut allergy |
| 02/19/2014 | CN103596588A Compositions for canine respiratory disease complex |
| 02/19/2014 | CN103596587A Filovirus fusion proteins and their uses |
| 02/19/2014 | CN103596586A Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |